Barrett Katz, MD, MBA, an internationally recognized Neuro-Ophthalmologist, serves as President and Chief Medical Officer of Retinagenix Therapeutics, Inc. Dr. Katz received his M.D. from Case-Western Reserve University School of Medicine after graduating from Colgate University. He did a residency in Internal Medicine at Parkland Hospital in Dallas, went to the National Institutes of Health in Neuro-Virology, completed a Neurology residency at Harvard Medical School and an Ophthalmology residency at Tufts-New England Medical Center. He studied at the National Hospital for Nervous Disease at Queen’s Square in London and served fellowships at Harvard and UCSF and obtained an MBA from the University of Rochester’s Simon School of Business. Prior to joining Retinagenix he served as CMO at GenSight Biologics and directed their gene therapy programs in LHON and RP. Dr. Katz was the Francis DeJur Chair of Ophthalmology at the Montefiore Medical Center and Albert Einstein College of Medicine in New York where he also served as Professor of Ophthalmology, Neurology and Neurosurgery, and the Executive Director of the Office of Clinical Trials. He has been engaged in the biotech industry and drug development space for many years and helped found a fellowship in Drug Development in Ophthalmology at the FDA. He previously served as CEO of Danube Pharmaceuticals, CMO of Fovea Pharmaceuticals and VP for Medical Affairs and Strategy at Eyetech. Dr. Katz has earned a reputation as a gifted clinician and teacher, an accomplished researcher, and a seasoned biotech executive.